The clinical role of genetic polymorphisms in drug-metabolizing enzymes

No abstract is available for this paper.

• Publication year

  2008

• Venue

  The Pharmacogenomics Journal

• Publication date

  2008-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.tpj.6500462PMID 17549068
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement

  2007cited by this paper
• Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine

  2006cited by this paper
• The c.−1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients

  2006cited by this paper
• Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

  2006cited by this paper
• Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN‐38 glucuronidation in Japanese patients with cancer

  2006cited by this paper
• The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis

  2006cited by this paper
• TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

  2006cited by this paper
• [The value of pharmacogenetic tests in antidepressive medication therapy].

  2005cited by this paper
• Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound

  2005cited by this paper
• Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?

  2005cited by this paper
• Pharmakogenomik in der klinischen Praxis

  2005cited by this paper
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

  2005cited by this paper
• The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

  2004cited by this paper
• CYP2C19 polymorphism and proton pump inhibitors.

  2004cited by this paper
• The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

  2004cited by this paper
• Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics

  2004cited by this paper
• UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer

  2004cited by this paper
• Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting

  2004cited by this paper
• Impact of the CYP2D6 Ultrarapid Metabolizer Genotype on Mirtazapine Pharmacokinetics and Adverse Events in Healthy Volunteers

  2004cited by this paper
• Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy

  2004cited by this paper
• CYP2D6 Genotype: Impact on Adverse Effects and Nonresponse During Treatment with Antidepressants—a Pilot Study

  2004cited by this paper
• Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

  2004cited by this paper
• CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole‐based quadruple therapy for eradication of Helicobacter Pylori

  2004cited by this paper
• Pharmacogenetics of Acenocoumarol Pharmacodynamics

  2004cited by this paper
• Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.

  2004cited by this paper
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

  2004cited by this paper
• Some aspects of genetic polymorphism in the biotransformation of antidepressants.

  2004cited by this paper
• The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.

  2004cited by this paper
• Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

  2004cited by this paper
• Acenocoumarol Stabilization is Delayed in CYP2C9*3 Carriers

  2004cited by this paper
• CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences

  2004cited by this paper
• Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.

  2004cited by this paper
• Pharmacogenomics of proton pump inhibitors.

  2004cited by this paper
• Determination of bleeding risk using genetic markers in patients taking phenprocoumon

  2003cited by this paper
• Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C9*1/*3 genotype

  2003cited by this paper
• Managing treatment-resistant major depression.

  2003cited by this paper
• Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine

  2003cited by this paper
• Pharmacogenetics of the Proton Pump Inhibitors: A Systematic Review

  2003cited by this paper
• Pharmacogenetics in cancer treatment.

  2003cited by this paper
• Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.

  2003cited by this paper
• Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in Humans

  2003cited by this paper
• Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype

  2002cited by this paper
• The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial

  2002cited by this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder

  2002cited by this paper
• Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

  2002cited by this paper
• Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.

  2002cited by this paper
• CYP2D6 Inhibition by Selective Serotonin Reuptake Inhibitors: Analysis of Achievable Steady‐State Plasma Concentrations and the Effect of Ultrarapid Metabolism at CYP2D6

  2002cited by this paper
• Polymorphism of the N‐acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug–induced hepatitis

  2002cited by this paper
• Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance

  2002cited by this paper
• Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

  2002cited by this paper
• Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

  2002cited by this paper
• Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil.

  2002cited by this paper
• N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.

  2001cited by this paper
• Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

  2001cited by this paper
• Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

  2001cited by this paper
• Metabolic gene polymorphism frequencies in control populations.

  2001cited by this paper
• Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.

  2001cited by this paper
• Drug development: Molecular targets for GI disease

  2001cited by this paper
• Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only.

  2001cited by this paper
• CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages

  2001cited by this paper
• Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

  2001cited by this paper
• Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.

  2001cited by this paper
• Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

  2001cited by this paper
• Effect of Fluoxetine on Carvedilol Pharmacokinetics, CYP2D6 Activity, and Autonomic Balance in Heart Failure Patients

  2001cited by this paper
• Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers

  2001cited by this paper
• Pathogenetic role of cyclooxygenase‐2 in hyperprostaglandin E syndrome/antenatal bartter syndrome: Therapeutic use of the cyclooxygenase‐2 inhibitor nimesulide

  2001cited by this paper
• N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review.

  2000cited by this paper
• Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

  2000cited by this paper
• Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.

  2000cited by this paper
• Pharmacogenetics of the Human Arylamine N-Acetyltransferases

  2000cited by this paper
• Venlafaxine serum levels and CYP2D6 genotype.

  2000cited by this paper
• Known variant DPYD alleles do not explain DPD deficiency in cancer patients.

  2000cited by this paper
• Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.

  2000cited by this paper
• Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

  2000cited by this paper
• Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

  2000cited by this paper
• Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

  2000cited by this paper
• The CYP2C19 Enzyme Polymorphism

  2000cited by this paper
• Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency.

  2000cited by this paper
• Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.

  1999cited by this paper
• The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations.

  1999cited by this paper
• Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E‐3174

  1999cited by this paper
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.

  1999cited by this paper
• Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

  1999cited by this paper
• Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia

  1999cited by this paper
• Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol

  1998cited by this paper
• Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

  1998cited by this paper
• Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.

  1998cited by this paper
• Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer

  1998cited by this paper
• Pharmacokinetics, dose adjustments, and 6‐mercaptopurine/ methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency

  1998cited by this paper
• Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate

  1998cited by this paper
• Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.

  1998cited by this paper
• Non-linear fluvoxamine disposition.

  1998cited by this paper
• Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine

  1997cited by this paper
• Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor.

  1997cited by this paper
• Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.

  1997cited by this paper
• Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

  1997cited by this paper
• Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

  1997cited by this paper
• Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance

  1997cited by this paper
• In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol.

  1997cited by this paper

• Can Pharmacogenetics Be Used to Predict the Response to Fesoterodine Fumarate?

  2025cites this paper
• NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors.

  2025cites this paper
• Antipsychotics use increases the risk of breast cancer in Women: Findings from systematic review and meta-analysis of observational studies

  2025cites this paper
• Overcoming antibiotic-resistant Helicobacter pylori infection: Current challenges and emerging approaches

  2025cites this paper
• Effects of red ginseng extract on the pharmacokinetics and disposition of warfarin via intestinal Cyp2c11 modulation in rats

  2023cites this paper
• Genetic polymorphisms of CYP2B6*6, CYP2C8*3 and CYP2D6*4 in vivax malaria patients from Brazilian Amazon

  2023cites this paper
• Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine

  2023cites this paper
• Personalized Approach in Eradication of Helicobacter pylori Infection

  2022cites this paper
• Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia

  2022cites this paper
• Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study

  2022cites this paper
• CBX2 in DSD: The Quirky Kid on the Block

  2022cites this paper
• Green tea polyphenols in cardiometabolic health: A critical appraisal on Phytogenomics towards personalized green tea

  2022cites this paper
• New Technologies and Precision Medicine: The Perfect Match?

  2022cites this paper
• Pharmacogenomics for the efficacy and side effects of antihistamines

  2022cites this paper
• Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China

  2022cites this paper
• Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs

  2021cites this paper
• Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data

  2021cites this paper
• Drug metabolism in animal models and humans: Translational aspects and chances for individual therapy

  2021cites this paper
• The effect of CYP2D6 and CYP2C9 gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy

  2021cites this paper
• Interaction of Phytocompounds of Echinacea purpurea with ABCB1 and ABCG2 Efflux Transporters.

  2021cites this paper
• Personalized Pharmacotherapy: A Historical Perspective on the Pharmacogenomics of Depression

  2021cites this paper
• The effect of CYP2D6 and CYP2C9 gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy

  2021cites this paper
• Liver Organoids: Recent Developments, Limitations and Potential

  2021cites this paper
• The role of DMPK science in improving pharmaceutical research and development efficiency.

  2021cites this paper
• Эффективность и безопасность послеоперационной аналгезии кеторолаком и трамадолом в зависимости от наличия полиморфизмов CYP2D6 и CYP2C9

  2021cites this paper
• CStone: A de novo transcriptome assembler for short-read data that identifies non-chimeric contigs based on underlying graph structure

  2021cites this paper
• Respuesta farmacogenética a escitalopram en pacientes geriátricos en Guatemala

  2020cites this paper
• Associations between CYP3A4, CYP3A5 and SCN1A Polymorphisms and Carbamazepine Metabolism in Epilepsy: A Meta-analysis

  2020cites this paper
• Proton Pump Inhibitor Switching Strategy after Failure of Standard Triple Therapy for Helicobacter pylori Infection

  2020cites this paper
• Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness

  2019cites this paper
• GENE AND DISEASE : AN ‘ ‘ OMICS ’ ’ AS THE PILLARS OF SYSTEMS MEDICINE

  2019cites this paper
• Measuring knowledge and attitudes towards the utilization of pharmacogenetic testing among physicians

  2019cites this paper
• High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis

  2019cites this paper
• Effects of CYP2C11 gene knockout on the pharmacokinetics and pharmacodynamics of warfarin in rats

  2019cites this paper
• Association between EPHX1 polymorphisms and carbamazepine metabolism in epilepsy: a meta-analysis

  2019cites this paper
• Introduction to Human Cytochrome P450 Superfamily

  2018cites this paper
• Different EPHX1 methylation levels in promoter area between carbamazepine-resistant epilepsy group and carbamazepine-sensitive epilepsy group in Chinese population

  2018cites this paper
• Eu/Tb luminescence for alkaline phosphatase and β-galactosidase assay in hydrogels and on paper devices.

  2018cites this paper
• GABAA receptor activity modulating piperine analogs: In vitro metabolic stability, metabolite identification, CYP450 reaction phenotyping, and protein binding.

  2018cites this paper
• Therapeutic Application of Pharmacogenomics in Oncology

  2016cites this paper
• Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?

  2016cites this paper
• Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.

  2016cites this paper
• The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs

  2016cites this paper
• Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.

  2016cites this paper
• Investigating the impact of missense mutations in hCES1 by in silico structure-based approaches

  2016cites this paper
• Proconvulsant effects of antidepressants - What is the current evidence?

  2016cites this paper
• Desipramine Increases Genioglossus Activity and Reduces Upper Airway Collapsibility during Non-REM Sleep in Healthy Subjects.

  2016cites this paper
• Clinical Applications of Pharmacogenomics in Cancer Therapy

  2016cites this paper
• Pharmacokinetics and metabolism of CNS-targeted natural products

  2016cites this paper
• DMD063750 1619..1631

  2015cites this paper
• Pharmacogenetics: an Emerging Therapeutic Option for Bangladesh

  2015cites this paper
• Special Section on Drug Metabolism and the Microbiome—Minireview Investigation of Host–Gut Microbiota Modulation of Therapeutic Outcome

  2015cites this paper
• Pharmacogenetics aspects of oral anticoagulants therapy

  2015cites this paper
• Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans.

  2014cites this paper
• PGx/Biomarker Utilization for Regulatory Decision Making

  2014cites this paper
• effects of ePhX 1 and cYP 3 a 4 polymorphisms on carbamazepine metabolism in epileptic patients

  2014cites this paper
• effects of ePhX 1 and cYP 3 a 4 polymorphisms on carbamazepine metabolism in epileptic patients

  2014cites this paper
• Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele.

  2014cites this paper
• effects of ePhX 1 and cYP 3 a 4 polymorphisms on carbamazepine metabolism in epileptic patients

  2014cites this paper
• effects of ePhX 1 and cYP 3 a 4 polymorphisms on carbamazepine metabolism in epileptic patients

  2014cites this paper
• The pharmacogenetics of drug metabolizing enzymes in the Lebanese population

  2014cites this paper
• effects of ePhX 1 and cYP 3 a 4 polymorphisms on carbamazepine metabolism in epileptic patients

  2014cites this paper
• CYP2C19 polymorphism influences Helicobacter pylori eradication.

  2014cites this paper
• effects of ePhX 1 and cYP 3 a 4 polymorphisms on carbamazepine metabolism in epileptic patients

  2014cites this paper
• effects of ePhX 1 and cYP 3 a 4 polymorphisms on carbamazepine metabolism in epileptic patients

  2014cites this paper
• Interactions between cytochrome P450 genetic polymorphisms and plasma organochlorines in non-Hodgkin lymphoma

  2014influential citation
• effects of ePhX 1 and cYP 3 a 4 polymorphisms on carbamazepine metabolism in epileptic patients

  2014cites this paper
• effects of ePhX 1 and cYP 3 a 4 polymorphisms on carbamazepine metabolism in epileptic patients

  2014cites this paper
• Pharmacotherapy Considerations in Cardiovascular Disease in Women: Therapeutic Implications for Cardiovascular Disease

  2014cites this paper
• Computational Methods in SNP Analysis

  2014cites this paper
• Computational approaches and resources in single amino acid substitutions analysis toward clinical research.

  2014cites this paper
• Neither Cytochrome P450 Family Genes nor Neuroendocrine Factors could Independently Predict the SSRIs Treatment in the Chinese Han Population

  2014cites this paper
• WITHDRAWN: Proconvulsant effects of antidepressants: What is the current evidence?

  2014cites this paper
• In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates

  2013cites this paper
• Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials

  2013cites this paper
• Functional diversity of the glutathione peroxidase gene family among human populations: implications for genetic predisposition to disease and drug response.

  2013cites this paper
• Gene Expression Variability in Human Hepatic Drug Metabolizing Enzymes and Transporters

  2013cites this paper
• Genetic Polymorphisms of Metabolic Enzymes and the Pharmacokinetics of Indapamide in Taiwanese Subjects

  2013cites this paper
• A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

  2013cites this paper
• Pharmacogenetics and Pharmacogenomics of Chronic Kidney Disease Comorbidities and Kidney Transplantation

  2013cites this paper
• The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population.

  2013cites this paper
• LOODUS- JA TEHNOLOOGIATEADUSKOND MOLEKULAAR- JA RAKUBIOLOOGIA INSTITUUT BIOTEHNOLOOGIA ÕPPETOOL

  2013cites this paper
• Development: In Vivo Pharmacology—Systems Biology in Health and Disease II

  2012cites this paper
• Do we need pharmacogenetics to personalize antidepressant therapy?

  2012cites this paper
• Neurobiological factors modulating H1-antihistamine induced cognitive impairment

  2012cites this paper
• Cytochrome P450 Pharmacogenetics: From Bench to bedside

  2012cites this paper
• Reduction-sensitive tioguanine prodrug micelles.

  2012cites this paper
• Pharmacogenetics: Matching the Right Foundation at Personalized Medicine in the Right Genomic Era

  2012cites this paper
• Looking to the future: incorporating genomic information into disparities research to reduce measurement error and selection bias.

  2012cites this paper
• Structural modelling pipelines in next generation sequencing projects.

  2012cites this paper
• Where are we today with personalized medicine?

  2012cites this paper
• Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

  2012cites this paper
• Is pharmacogenetic CYP 2 D 6 testing useful ?

  2011cites this paper
• Pharmacogenetics in geriatric medicine: challenges and opportunities for clinical practice.

  2011cites this paper
• Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype

  2011cites this paper
• Drug–Drug Interactions: Designing Development Programs and Appropriate Product Labeling

  2011cites this paper
• THE INFLUENCE OF POLYMORPHISMS IN CYP 2 C 9 AND VKORC 1 GENES ON THE EFFICACY AND SAFETY OF ORAL ANTICOAGULANT TREATMENT

  2011cites this paper
• A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks

  2011cites this paper
• Pharmacogenomics of antidepressant treatment effects

  2011cites this paper
• CYP2D6 Genotyping in Natives and Immigrants from the Emilia-Romagna Region (Italy)

  2011cites this paper